COMMERCIALISATION | CORNER
Te questionnaire was performed at two time points. First, in 2010, we requested technical and managerial product development professionals were asked for to provide TRL levels of technologies in years 2010, 2015 and 2025 though a process where each technology readiness level was explained to them. Following this, the questionnaire was sent out in 2014 generating predictive values for 2015, 2020 and 2030, enabling more robust statistical analysis prior to the release of the MANCEF pharmaceutical roadmap. Below, in tables 1 and 2, we provide the results of our updated TRL analysis for the year 2015. An analysis of all the remaining time points, including 2020 and 2030, can be found in the recently published MANCEF Pharmaceutical Landscape.
Technology Chemistry Biology
Comp. Science
Table 1: Individual Technology Ratings 2015 Average TRL 7.538 6.231 6.231
Minimum TRL 6 TRL 5 TRL 6
Table 2: TRL Technology Set Score 2015 Type
Set average method
Robert M. Giasolli currently serves on MANCEF’s North American Board and is the Co-Founder, CTO, and VP of Research and Development for Cagent Vascular, LLC. Mr. Giasolli is an applied physicist and serial
Maximum TRL 9 TRL 8 TRL 9
entrepreneur, having co-founded five companies, which collectively have raised over $50 million. He has over 15 years of executive experience with more than 50 patents filed. His career in product development has included design and product development in micro and nanotechnology, including products in RF switching, optical spliting, hydrocarbon sensing, biomedical devices, and ballistic safety and arming.
Average 6.9382
Dr. Yorgos Marinakis has a Ph.D. in Biology, is a patent atorney and a Technology Entrepreneurship student at Nikos. He was the main author of the Organic Photovoltaic roadmap and an expert in disruptive technology-based entrepreneurial action.
One company that has used the Pharmaceutical Landscape to choose between differing technologies and technology set pathways to develop its internal roadmapping effort is Cagent Vascular LLC. Figure 1 shows the Cagent Smart Balloon that uses micro machining technology to produce surgical-like incisions to prepare vessels for follow-on therapies in the body. Due to its unique design and assembly the device can be coated with nanotechnology-enhanced pharmaceutical agents to further aid in vessel healing.
Te MANCEF “Tird-Generation Roadmap” or “Landscape” was developed with the use of Technology Readiness Levels and Technology Readiness Assessment techniques. Tis choice became essential to address multi-technology based products. A growing number of products, especially in the pharmaceutical industry, require roadmaps addressing multi-dimensional technology architecture to assist their product development teams. MANCEF provides a third-generation roadmap design in the pharmaceutical landscape as a solution.
Dr. Robert Tierney graduated from the University of Twente Nikos in the field of technology innovation. He was a student hire at Sandia National Laboratory. He has a biology degree and a management of
technology and Innovation Masters degree from the University of New Mexico. He has had five ISI ranked journal publications in the last three years.
Dr. Steven Walsh is a distinguished professor at the University of New Mexico and an Institute professor at the University of Twente. He is also the Regents professor at UNM’s Anderson School of Management. He has many
business service awards including the lifetime achievement award for commercialization of Micro and Nano technology firms from MANCEF. He has also been named as a Tech All Star from the State of New Mexico Economic Development Department and has been recognised by Albuquerque the magazine as a leader in service to the economic community. Recently he was ranked in the top ten researchers for the last decade in innovation research by IAMOT and the top four researchers in the field of Technology Entrepreneurship.
48 | commercial micro manufacturing international Vol 7 No.6
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52